Generic Medicine Info
Indications and Dosage
Allergic conjunctivitis, Allergic rhinitis, Urticaria
Adult: 20 mg once daily.
Child: ≥12 yr Same as adult dose.
Should be taken on an empty stomach. Take 1 hr before or 2 hr after intake of food or fruit juice.
Special Precautions
Pregnancy and lactation.
Adverse Reactions
Headache, malaise, abdominal pain, diarrhoea, increased appetite, wt gain, thirst, gastritis, prolonged QT interval, dyspnoea, anxiety, insomnia, vertigo, dizziness, pyrexia, oral herpes, tinnitus.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Symptoms: Dizziness, headache and nausea. Management: Symptomatic and supportive treatment.
Drug Interactions
Increased risk of adverse effects w/ P-glycoprotein inhibitors (e.g. ketoconazole, erythromycin, ciclosporin, ritonavir, diltiazem) esp in patients w/ moderate to severe renal impairment.
Food Interaction
Decreased bioavailability w/ food and grapefruit juice.
Description: Bilastine inhibits immune system reactions mediated by the interaction of histamine on its H1-receptor.
Absorption: Rapidly absorbed from the GI tract. Bioavailability: 61%. Time to peak plasma concentration: Approx 1.3 hr.
Distribution: Plasma protein binding: 84-90%.
Excretion: Via urine (28.3%) and faeces (66.5%) as unchanged drug. Elimination half-life: 14.5 hr.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX29 - bilastine ; Belongs to the class of other antihistamines for systemic use.
Buckingham R (ed). Bilastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 22/09/2015.

Joint Formulary Committee. Bilastine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 22/09/2015.

Disclaimer: This information is independently developed by MIMS based on Bilastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in